STENTiT is a medical device spin-off company from the Dutch Eindhoven University of Technology, focusing on the development of regenerative endovascular implants. These bioresorbable devices trigger a natural healing response by the circulating blood cells, in which the implant is being replaced by new vascular tissue to restore the artery from the inside-out. Since the establishment of the company in 2017, STENTiT has received broad international recognition and awards for its high-potential approach, covering world leading stages. As the company is currently going through the next translational phases, STENTiT is on its way to fulfill its ambition to become the new standard in endovascular treatment, providing a life-lasting solution for millions of patients around the world.
| Website | http://www.stentit.com |
| Employees | 17 (13 on RocketReach) |
| Founded | 2017 |
| Technologies |
JavaScript
,
HTML
,
PHP
+7 more
(view full list)
|
| Industry | Medical Equipment Manufacturing, Medical, Health Care |
| Keywords | Endovascular Devices, Regenerative Medicine, Medical Devices, Blood Vessel Repair, Tissue Regeneration, Biocompatible Materials, Natural Healing, Interventional Cardiology, Vascular Surgery, Innovative Medical Solutions, Drug Eluting Stents, Peripheral Vascular Disease, Minimally Invasive Surgery, Therapeutic Devices |
| Competitors | Johnson & Johnson, Medtronic, Abbott, Cardinal Health, Boston Scientific, Smith+Nephew, Cook Medical, BIOTRONIK, CR Bard - Europe, Middle East and Africa (EMEA), Terumo +39 more (view full list) |
Looking for a particular STENTiT employee's phone or email?
Bart Sanders is the CEO and Founder of STENTiT.
13 people are employed at STENTiT.